35岁以下宫颈癌的分子病理特征分析  

Molecular Pathology Features of Cervical Cancer Patients Under 35 Years

作　　者：刘镜文 陈莉[2] 吴秋良[3] 

机构地区：[1]惠州市第一妇幼保健院病理科,广东惠州516000 [2]东莞市虎门医院妇产科,广东东莞523900 [3]中山大学肿瘤防治中心病理科,广东广州510060

出　　处：《肿瘤基础与临床》2016年第4期324-326,共3页journal of basic and clinical oncology

摘　　要：目的探讨35岁以下宫颈癌的分子病理特征,为今后的临床诊治工作提供可靠的参考依据。方法抽取获得临床明确诊断的35岁以下宫颈癌患者49例,将其作为观察组,另抽取同期收治的52例35岁以上宫颈癌患者作为对照组,对这2组患者的临床资料展开回顾性对比分析。结果观察组患者的5 a生存率为65.6%,低于对照组的84.4%,差异有统计学意义(P<0.05);观察组患者survivin、MMP-2、CD44v6的相对表达量较对照组显著升高,差异均有统计学意义(P均<0.05);而TIMP-2水平明显低于对照组,差异有统计学意义(P<0.05)。结论对于35岁以下宫颈癌患者而言,其预后效果相对较差,分子病理学研究显示,这可能与survivin、MMP-2、CD44v6、TIMP-2的表达异常等有关,在今后的研究与治疗中应对其给予足够的重视,将此因素作为突破点对患者实施生物治疗可有效改善患者预后。Objective To investigate the molecular pathology features of cervical cancer patients under 35 years and to provide a reliable reference for the clinical diagnosis and treatment in the future. Methods Forty-nine cases cervi-cal cancer under 35 years old were collected as the study group,and the other 52 cases of cervical cancer over the age of 35 at the same period were treated as the control group,the clinical data of the two groups were retrospectively ana-lyzed. Results The 5-year survival rate in the study group was 65. 6% ,and was 84. 4% in the control group（P ﹤0. 05）;the expressions of levels surviving,MMP-2,CD44v6 in the study group were significantly higher than those in the control group（P ﹤ 0. 05）;the TIMP-2 level in the study group was lower than that in the control group（P ﹤0. 05）. Conclusion The prognosis of cervical cancer patients under 35 years is poor,molecular pathology studies have shown that this may be related to the abnormal expressions of survivin,MMP-2,CD44v6 and TIMP-2.

关 键 词：宫颈癌 SURVIVIN 基质金属蛋白酶-2 CD44V6 基质金属蛋白酶抑制剂-2 

分 类 号：R737.33[医药卫生—肿瘤]